Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine
Bibliographic record
Abstract
This narrative review used manufacturer-sponsored vortioxetine clinical trial database (doses of 5-20 mg) to evaluate the effect of vortioxetine treatment on short- and long- term functional outcomes in major depressive disorder (MDD), in both the clinical trial setting and in routine practice. The Sheehan Disability Scale (SDS) was the most used functional scale and, based on this measure, short-term, placebo-controlled studies demonstrated significant improvements with vortioxetine 10 mg (reductions ranged from -0.92 to -2.10 points vs placebo after 6-8 weeks treatment) and 20 mg (reductions ranged from -0.88 to -3.92 vs placebo). Of note, the acute beneficial effects of vortioxetine on functionality were seen in patients with severe baseline depressive symptoms as well as those with significant anxiety. Long-term open-label extension studies further showed that maintenance treatment was associated with continued functional improvements over one year (reaching an average reduction of -6.2 SDS points from baseline) that were correlated with continued improvements in residual symptoms. Evidence from real-world studies, using multiple functional outcomes, further demonstrated generalizability to routine practice where patients are living with multiple comorbidities previously excluded from the randomized controlled trials. Taken overall, the findings from several head-to-head studies indicated a functional advantage of vortioxetine compared with other classes of antidepressants and demonstrated the effectiveness of vortioxetine as first-line treatment while also confirming its effectiveness in improving functional outcomes when given later in the treatment journey. In summary, vortioxetine is an effective treatment option for improving functional outcomes in people living with MDD.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.016 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.003 |
| Bibliometrics | 0.003 | 0.003 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.002 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".